CONTRIBUTION OF OATP (ORGANIC ANION-TRANSPORTING POLYPEPTIDE) FAMILY TRANSPORTERS TO THE HEPATIC UPTAKE OF FEXOFENADINE IN HUMANS

Fexofenadine hydrochloride (FEX), a second generation H1-receptor antagonist, is mainly eliminated from the liver into bile in unchanged form. Recent studies have shown that FEX can be accepted by human MDR1 (P-glycoprotein), OATP1A2 [organic anion-transporting polypeptide (OATP)-A, and OATP2B1 (OATP-B)] expression systems. However, other transporters responsible for the hepatic uptake of FEX have not yet been identified. In the present study, we evaluated the contribution of OATP family transporters, namely OATP1B1 (OATP2/OATP-C), OATP1B3 (OATP8), and OATP2B1 (OATP-B), to FEX uptake using transporter-expressing HEK293 (human embryonic kidney) cells. The uptake of FEX in OATP1B3-expressing cells was significantly greater than that in vector-transfected cells. On the other hand, OATP1B1- or OATP2B1-mediated uptake of FEX was not statistically significant. OATP1B3-mediated transport could be explained by a one-saturable component with a Michaelis constant (Km) of 108 ± 11 μM. The inhibitory effect of FEX on the uptake of estrone-3-sulfate (E1S), cholecystokinin octapeptide (CCK-8), and 17β-estradiol-17β-d-glucuronide (E217βG) was also examined. Both OATP1B1- and OATP1B3-mediated E217βG uptake was inhibited by FEX. The Ki values were 148 ± 61 and 205 ± 72 μM for OATP1B1 and OATP1B3, respectively. FEX also inhibited OATP1B3-mediated CCK-8 uptake and OATP1B1-mediated E1S uptake with a Ki value of 83.3 ± 15.3 and 257 ± 84 μM, respectively, suggesting that FEX could not be used as a specific inhibitor for OATP1B1 and OATP1B3, although FEX was preferentially accepted by OATP1B3. In conclusion, this is, to our knowledge, the first demonstration that OATP1B3 is thought to be a major transporter involved in hepatic uptake of FEX in humans.

[1]  Yuichi Sugiyama,et al.  Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics , 2003, Clinical pharmacology and therapeutics.

[2]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.

[3]  P. Neuvonen,et al.  High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). , 2004, Pharmacogenetics.

[4]  Y. Sawada,et al.  CITRUS JUICES INHIBIT THE FUNCTION OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP-B , 2005, Drug Metabolism and Disposition.

[5]  U. Hofmann,et al.  Determination of fexofenadine in human plasma and urine by liquid chromatography-mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[6]  P. Meier,et al.  The superfamily of organic anion transporting polypeptides. , 2003, Biochimica et biophysica acta.

[7]  Bruno Stieger,et al.  Enterohepatic bile salt transporters in normal physiology and liver disease. , 2004, Gastroenterology.

[8]  D. Keppler,et al.  A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[9]  U. Hofmann,et al.  Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). , 2005, British journal of clinical pharmacology.

[10]  A. Brown,et al.  Cardiovascular safety of fexofenadine HCl , 1999, Clinical and Experimental Allergy.

[11]  Steffen Bauer,et al.  Evidence for Inverse Effects of OATP‐C (SLC21A6) *5 and *1b Haplotypes on Pravastatin Kinetics , 2004, Clinical pharmacology and therapeutics.

[12]  J. Nezu,et al.  Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human , 2004, Journal of Pharmacology and Experimental Therapeutics.

[13]  G R Wilkinson,et al.  OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[14]  J. Nezu,et al.  Involvement of Human Organic Anion Transporting Polypeptide OATP-B (SLC21A9) in pH-Dependent Transport across Intestinal Apical Membrane , 2003, Journal of Pharmacology and Experimental Therapeutics.

[15]  P. Dawson,et al.  Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine , 2002, Clinical pharmacology and therapeutics.

[16]  D. Keppler,et al.  Localization and Genomic Organization of a New Hepatocellular Organic Anion Transporting Polypeptide* , 2000, The Journal of Biological Chemistry.

[17]  Y. Sugiyama,et al.  Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. , 1997, The Journal of pharmacology and experimental therapeutics.

[18]  Peter J. Meier,et al.  Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties , 2004, Pflügers Archiv.

[19]  L Landmann,et al.  Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. , 2001, Gastroenterology.

[20]  B. Haehner‐Daniels,et al.  The effect of rifampin administration on the disposition of fexofenadine , 2001, Clinical pharmacology and therapeutics.

[21]  D. Keppler,et al.  Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). , 2004, Pharmacogenetics.

[22]  P. Meier,et al.  Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver , 2001 .

[23]  H. Lennernäs,et al.  The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. , 2003, British journal of clinical pharmacology.

[24]  K. Maeda,et al.  Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans , 2004, Journal of Pharmacology and Experimental Therapeutics.

[25]  P. Meier,et al.  Interactions of glycyrrhizin with organic anion transporting polypeptides of rat and human liver. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[26]  B. Jarvis,et al.  Fexofenadine , 2000, Drugs.